Feasibility evaluation of N-Isopropyl Acrylamide 3D gel dosimeters for proton therapy.

This study aimed to investigate the feasibility of applying 3D gel dosimeters for proton therapy. Two different formulations (5-5-3-5, 5-3-3-10) for the N-Isopropyl Acrylamide (NIPAM) polymer gel were used to find the best composition for the application of NIPAM polymer gels for proton therapy. The reaction of the gel under different physical conditions, including dependence on energy and dependence on the dose rate of the NIPAM gel under proton irradiation, was also explored. A NIPAM gel dosimeter was used to record the 3D dose distribution, and a self-developed parallel beam optical computed tomography scanner was used to obtain non-irradiated and post-irradiated gel phantom images. The NIPAM gel was filled into a cylindrical acrylic phantom. The results showed that the optical density of the irradiated NIPAM dosimeter was linear in the dose range of 0 to 6 Gy, and the linearity of the two NIPAM gel formulations at the depth of the dose point (2 cm) was 0.98 to 0.89. The dose depth curves showed different patterns with different gel sensitivities. This study demonstrated that the NIPAM gel dosimeter with the 5-3-3-10 formulation is suitable for verifying the dosimetry dose of proton beams.

Significant Reduction in Vertebral Artery Dose by Intensity Modulated Proton Therapy: A Pilot Study for Nasopharyngeal Carcinoma.

Intensity modulated proton therapy (IMPT) with the vertebral artery (VA)-sparing technique has been initially proposed in our institution. This pilot study was conducted to compare the dose to VAs between IMPT and volumetric-modulated arc therapy (VMAT) for patients with nasopharyngeal carcinoma (NPC). A total of six patients with NPC treated by IMPT were enrolled in the study. Target volumes and organs at risk (OARs) were delineated, including 12 samples of right and left VAs, respectively, for each patient. Treatment planning by IMPT and dual-arc VMAT was carried out for comparison. The IMPT plan significantly reduced VA mean dose, V10, V20, V30, V40, and V50, compared to the VMAT plan in all 12 samples (p < 0.001). The average mean dose to VAs for IMPT was 35.2% (23.4-46.9%), which was less compared to VMAT (p < 0.001). Adequate dose coverage was achieved with both IMPT and VMAT plans for three different dose levels of target volumes for all patients. IMPT significantly reduces VA dose while maintaining adequate dose coverage of all target volumes. For patients with head and neck cancer who seek to preserve their blood flow to the brain in order to decrease late vascular and neurologic sequelae, IMPT should be considered. A prospective study with longer follow-up is ongoing to confirm our preliminary results.